This revealed that PPAR-γ agonists serve as negative transcriptional regulators of STAT5 and its downstream targets HIF2α and CITED2, which are key guardians of quiescence and stemness in CML LSCs (138). Here, PPARG is linked to chronic myelogenous leukemia, BCR-ABL1 positive.